A patient who is on clozapine therapy is being monitored for metabolic syndrome. Which set of nurse findings is consistent with a diagnosis of metabolic syndrome.

Metabolic syndrome is a cluster of conditions that together significantly increase the risk of cardiovascular disease and type 2 diabetes. According to widely used diagnostic criteria (such as those from the National Cholesterol Education Program Adult Treatment Panel III), metabolic syndrome requires at least three of the following: abdominal obesity (waist circumference greater than 102 cm in men or 88 cm in women), elevated fasting blood glucose (at or above 100 mg/dL), elevated triglycerides, low HDL cholesterol, and elevated blood pressure (at or above 130/85 mm Hg). The second option — fasting blood glucose of 178 mg/dL, blood pressure of 156/98 mm Hg, and waist circumference of 110 cm — satisfies three of these criteria simultaneously and is therefore consistent with a metabolic syndrome diagnosis. Clozapine is associated with metabolic syndrome due to its effects on insulin resistance, weight gain, and dyslipidemia. The first option describes fever and tachycardia, which suggest infection or agranulocytosis, a different clozapine concern. The third option focuses on oxygenation and respiratory rate, which are not metabolic syndrome criteria. The fourth option with dilated pupils and headache relates to neurological findings, not metabolic syndrome.